Related Experiment Video

Updated: Feb 12, 2026

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

12.1K

Comparison of Clinical Outcomes in Patients With Acute Myocardial Infarction Between Those With and Without Metabolic

Eiichi Shiraki1, Kenichi Sakakura1, Hiroyuki Jinnouchi1

  • 1Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University Saitama Japan.

Circulation Reports
|February 11, 2026
PubMed
Abstract

Insights

Metabolic dysfunction-associated fatty liver disease (MAFLD) did not significantly impact major adverse cardiovascular events (MACE) in acute myocardial infarction (AMI) patients post-PCI. Further research is needed to clarify the long-term clinical outcomes in this patient group.

Area of Science:

  • Cardiology
  • Hepatology
  • Internal Medicine

Background:

  • Acute myocardial infarction (AMI) is a critical cardiovascular condition with variable prognoses.
  • Emerging evidence links cardiovascular diseases with metabolic dysfunction-associated fatty liver disease (MAFLD).
  • The prognostic significance of MAFLD in AMI patients requires further investigation.

Purpose of the Study:

  • To examine the association between MAFLD and clinical outcomes in patients who have experienced AMI.
  • To determine if MAFLD influences the occurrence of major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) for AMI.

Main Methods:

  • Retrospective analysis of 1,142 AMI patients undergoing PCI.
  • Classification into MAFLD (n=231) and non-MAFLD (n=911) groups based on computed tomography (CT) liver-to-spleen attenuation ratio.
  • Primary outcome defined as major adverse cardiovascular events (MACE): all-cause death, non-fatal myocardial infarction, or heart failure readmission.

Main Results:

  • MACE occurred less frequently in the MAFLD group compared to the non-MAFLD group during a median follow-up of 609 days (P=0.015).
  • Multivariate Cox hazard analysis revealed no significant association between MAFLD and MACE (HR 0.80, P=0.219) after adjusting for confounders.

Conclusions:

  • This study found no significant association between MAFLD and MACE in AMI patients.
  • The findings suggest that MAFLD may not strongly influence long-term clinical outcomes in patients with acute myocardial infarction.
Keywords:
Acute myocardial infarctionComputed tomographyMetabolic dysfunction-associated fatty liver disease (MAFLD)Outcomes

More Related Videos

Myocardial Infarction and Functional Outcome Assessment in Pigs12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.7K
Acute Myocardial Infarction in Rats07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

54.7K

Related Concept Videos

Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
37.2K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.0K
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
891
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
245
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
448
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
984